Skip to main content
. Author manuscript; available in PMC: 2014 Oct 9.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2014 Jan 14;7(1):78–85. doi: 10.1161/CIRCOUTCOMES.113.000674

Figure.

Figure

Effectiveness and costs of selected key hospital-based treatment strategies for patients with acute myocardial infarction (AMI) in China. The slope of lines in the figure represents the incremental cost-effectiveness ratios by comparing each 1 of a succession of combination treatment strategies to the prior simpler strategies. Shallower slopes are more cost-effective; steep slopes less cost-effective. A1, Four oral drugs in patients with AMI (aspirin, β-blockers, angiotensin-converting enzyme inhibitors, and statins). A2, Clopidogrel in patients with AMI. B, Unfractionated heparin in patients with non–ST-segment–elevation myocardial infarction (NSTEMI). C1, Primary percutaneous coronary intervention (PCI) in tertiary hospitals and thrombolysis with streptokinase in secondary hospitals in patients with ST-segment–elevation myocardial infarction (STEMI). C2, Primary PCI in all patients with STEMI. C3, Primary PCI in high-risk patients with NSTEMI in tertiary hospitals. QALYs indicates quality-adjusted life years.